Hengrui Pharmaceuticals Gets Chinese Drug Regulator's Nod to Trial Two Cancer Drugs

MT Newswires Live11-05

Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276), through its subsidiaries, received approval from China's National Medical Products Administration for clinical trials of two cancer drugs, according to a Wednesday disclosure on the Shanghai bourse.

The pharmaceutical company will trial RC48B (rikang trastuzumab) for injection and the adebrelimab injection.

RC48B will be tested in combination with a PD-1/PD-L1 inhibitor as a treatment for patients with resectable non-squamous non-small cell lung cancer with HER2 abnormalities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment